Capital raised by Strand Therapeutics
1 Form D filing · first filed May 2025 · Boston, MA
Chief Executive Officer
Signatory on Strand Therapeutics's Form D filings · $108.1M raised across 1
Jacob Becraft is on file as Chief Executive Officer at Strand Therapeutics in Boston, MA. Strand Therapeutics has 1 Form D filing on record, $108.1M raised in total. Jacob Becraft appears as a signatory on the company's filings.
STX-001 is a programmable mRNA therapy candidate designed for the treatment of solid tumors. It utilizes a multi-modal synthetic self-replicating mRNA technology to deliver a prolonged and locally-acting IL-12 cytokine directly into the tumor microenvironment. The therapy has received Investigational New Drug (IND) clearance from the FDA and is currently in Phase 1 clinical trials.
